Another Reason To Watch Kite's CAR-T Results At ASH
This article was originally published in Scrip
Executive Summary
Kite Pharma CEO Arie Belldegrun confirmed on Aug. 17 that a patient died soon after treatment with the company's chimeric antigen receptor T-cell (CAR-T) therapy during the Phase I portion of an ongoing Phase I/II clinical trial, but he said the death was not related to Kite's closely-watched cancer therapy.
You may also be interested in...
Finance Watch: Mega-Rounds Around The World As VCs Spread The Wealth
Private Company Edition: After US-based Alumis and Sionna raised $259m and $182m, respectively, in series C rounds, Tubulis in Munich, Germany brought in €128m ($138.8m) in series B2 cash, while Rakuten – with offices in the US, Europe and Asia – closed a $119m series E round.
Finance Watch: The Biggest Biopharma IPO Of 2024 May Not Happen In The US
Public Company Edition: Galderma proposed pricing for its $2.6bn Swiss public market debut. Also, Apogee and Akero lead follow-on offerings with $483m and $366.9m, respectively, and Lexicon’s private placement brings in $250m, while Spruce reveals a 21% workforce reduction.
Novartis Goes All In On A Second Long-Term Bet With IFM
Deal Snapshot: Novartis partnered with IFM Due in 2019 and has now exercised an option to buy the IFM Therapeutics subsidiary, continuing its ongoing relationship with the group.